EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Mabpharm's enterprise value is HK$1,518.26 Mil.
Mabpharm's EBITDA for the trailing twelve months (TTM) ended in Dec. 2023 was HK$-152.13 Mil. Therefore, Mabpharm's EV-to-EBITDA for today is -9.98.
The historical rank and industry rank for Mabpharm's EV-to-EBITDA or its related term are showing as below:
HKSE:02181'
s EV-to-EBITDA Range Over the Past 10 Years
Min: -18.72 Med: -11.68 Max: -4.59
Current: -9.98
During the past 7 years, the highest EV-to-EBITDA of Mabpharm was -4.59. The lowest was -18.72. And the median was -11.68.
HKSE:02181's EV-to-EBITDA is ranked worse than 100% of 451
companies
in the Biotechnology industry
Industry Median: 9.15
vs HKSE:02181: -9.98
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
As of today (2024-06-05), Mabpharm's stock price is HK$0.345.
Mabpharm's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 was HK$-0.055. Therefore, Mabpharm's PE Ratio for today is At Loss.
The "classic" EV-to-EBITDA is much better in capturing debt and net cash than the PE Ratio.
Mabpharm EV-to-EBITDA Historical Data
The historical data trend for Mabpharm's EV-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Mabpharm's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Mabpharm's EV-to-EBITDA Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Mabpharm's EV-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Mabpharm's EV-to-EBITDA falls into.
Mabpharm EV-to-EBITDA Calculation
Mabpharm's EV-to-EBITDA for today is calculated as:
Mabpharm's current Enterprise Value is HK$1,518.26 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Mabpharm's EBITDA for the trailing twelve months (TTM) ended in Dec. 2023 was HK$-152.13 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Mabpharm (HKSE:02181) EV-to-EBITDA Explanation
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
Mabpharm's share price for today is HK$0.345.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Mabpharm's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 was HK$-0.055.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio.
Thank you for viewing the detailed overview of Mabpharm's EV-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.
Mabpharm Ltd is a biopharmaceutical company. The company is engaged in the research, development, and production of new drugs and biosimilars for cancers and autoimmune diseases. Its core products include CMAB008 (infliximab), CMAB007 (omalizumab), and CMAB009 (cetuximab).
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
HKSE:02181 has been successfully added to your 